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Background: Chemotherapy with trastuzumab is widely used for patients with human epidermal growth factor
receptor 2-positive (HER2+) breast cancer, but a significant number of patients with the tumor fail to respond, or
relapse. The mechanisms of recurrence and biomarkers that indicate the response to the chemotherapy and
outcome are not fully investigated.
Methods: Genomic alterations were analyzed using single-nucleotide polymorphism arrays in 46 HER2
immunohistochemistry (IHC) 3+ or 2+/fluorescent in situ hybridization (FISH)+ breast cancers that were treated with
neoadjuvant chemotherapy with paclitaxel, cyclophosphamid, epirubicin, fluorouracil, and trastuzumab. Patients
were classified into two groups based on presence or absence of alterations of 65 cancer-associated genes, and the
two groups were further classified into four groups based on genomic HER2 copy numbers or hormone receptor
status (HR+/−). Pathological complete response (pCR) and relapse-free survival (RFS) rates were compared between
any two of the groups.
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Results and discussion: The pCR rate was 54% in 37 patients, and the RFS rate at 3 years was 72% (95% CI, 0.55-
0.89) in 42 patients. The analysis disclosed 8 tumors with nonamplified HER2 and 38 tumors with HER2 amplification,
indicating the presence of discordance in tumors diagnosed using current HER2 testing. The 8 patients showed
more difficulty in achieving pCR (P=0.019), more frequent relapse (P=0.018), and more frequent alterations of genes
in the PI3K pathway (P=0.009) than the patients with HER2 amplification. The alterations of the PI3K and estrogen
receptor (ER) pathway genes generally indicated worse RFS rates. The prognostic significance of the alterations was
shown in patients with a HR+ tumor, but not in patients with a HR- tumor when divided. Alterations of the PI3K
and ER pathway genes found in patients with a HR+ tumor with poor outcome suggested that crosstalk between
the two pathways may be involved in resistance to the current chemotherapy with trastuzumab.
Conclusions: We recommend FISH analysis as a primary HER2 testing because patients with IHC 2+/3+ and
nonamplified HER2 had poor outcome. We also support concurrent use of trastuzumab, lapatinib, and cytotoxic and
anti-hormonal agents for patients having HR+ tumors with alterations of the PI3K and ER pathway genes.
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Complete pathological response, Relapse-free survivalBackground
Patients with human epidermal growth factor receptor 2
(HER2)-positive (HER2+) breast cancer were known to
have a poor prognosis in the era when trastuzumab was
not available [1-3]. After the introduction of trastuzumab,
the outcome of HER2+ operable patients changed signifi-
cantly, and many patients who achieved a pathological
complete response (pCR) were expected to have been
cured of the disease [2,3]. However, pCR rates are 30-60%,
and the 3-year relapse-free survival (RFS) is 71-78% in
patients with operable breast cancer, indicating that a
substantial number of patients who undergo surgical re-
section after the chemotherapy have recurrence [2,3]. Pa-
tients with HER2+ breast cancer are usually treated with a
combination of trastuzumab and taxanes with or without
other chemotherapeutic agents [1-3], but predictors that
indicate the response to the chemotherapy and outcome
are not fully investigated.
Alterations in the HER2-PI3K-AKT pathway, which
include expression of an extracellular domain-truncated
HER2 (p95HER2), mutation and amplification of PIK3CA,
loss of PTEN or INPPB4, and mutation of AKT1, are
known to result in a poor response to chemotherapy with
trastuzumab or poor outcome for breast cancer patients
[4,5]. In addition, there are two types of HER2+ breast
cancer; namely, hormone receptor (HR)-positive (HR+)
and HR-negative (HR-), and some investigators have
reported different biological characteristics including
pathological responses between the two [6,7]. Crosstalk
between the estrogen receptor (ER) pathway and the PI3K
or ERK/MAPK pathway is thought to be involved in the
resistance to trastuzumab-containing chemotherapy in
HER2+/HR+ breast cancer [8]. However, there have been
few studies aiming to resolve the mechanism of chemo-
therapy resistance or to identify biomarkers that indicate
pCR and relapse using clinical samples.It has been reported that 0.9% - 18.5% of HER2 immu-
nohistochemistry (IHC) 3+ tumors had a single copy of
HER2 [8]. The technical shortcomings of IHC that can
result in false-positive and false-negative results may be
one of the reasons for the discordance between IHC
grades and HER2 copy numbers [9,10], however, there
may be true single-gene overexpressers although the
incidence may be low. Although metastatic breast cancer
patients with the discordance between IHC and HER2
copy numbers seemed to show a low probability of
responding to HER2-targeted therapy [11], there has
been no study to clarify that single-gene overexpressers
with operable breast cancer will respond to trastuzumab,
and the mechanisms for the possible resistance to the
trastuzumab-containing chemotherapy.
An alternatively spliced form of the human HER2
gene, Δ16HER2, containing an in-frame deletion was
found in human breast cancer [12]. Mitra et al. showed
that ectopic expression of the Δ16HER2 transcript, but
not wild-type HER2 transcript, promotes receptor
dimerization, cell invasion, and trastuzumab resistance
in NIH3T3 and MCF7 tumor cells [13]. More recently,
it was reported that Δ16HER2-expressing transgenic
mice, but not wild-type HER2-expressing mice, devel-
oped multiple mammary adenocarcinomas [14]. How-
ever, the clinical significance of Δ16HER2 has not been
fully examined in human breast cancer.
We hypothesized that genomic alterations detectable
by single-nucleotide polymorphism (SNP) arrays and
HER2 copy numbers and levels of HER2 transcripts
would suggest mechanisms of resistance and prognostic
factors for patients treated with trastuzumab-containing
chemotherapy. Thus, we studied SNP array patterns of
143 breast cancer samples, including 46 HER2+ tumors,
obtained at the time of diagnosis. We found that alter-
ations of genes involved in the estrogen-receptor (ER)
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with a HR+ but not HR- tumor, who were treated with
chemotherapy with trastuzumab, followed by adjuvant
trastuzumab (plus endocrine therapy for patients with a
HR+ tumor). We also found that patients with a tumor
showing a single HER2 copy number had more difficulty
in achieving pCR, and tended to have worse RFS rates
than those having a tumor with HER2 amplification.
These findings may help to clarify the mechanisms for
resistance to the chemotherapy with trastuzumab, and
improve the efficacy of chemotherapy in HER2+ breast
cancer.
Methods
Patients and samples
One hundred and fifty four tumor tissue and peripheral
blood samples were obtained from 152 Japanese women,
including two with bilateral tumors, who underwent a
diagnostic core-needle biopsy between April 2005 and
August 2011. The first specimen was used for the patho-
logical diagnosis with H&E staining, the determination
of ER, progesterone receptor (PgR), and HER2 status
using IHC, and fluorescent in situ hybridization (FISH)
[15]. The second and third specimens, which were dir-
ectly frozen in liquid nitrogen, were used for DNA ana-
lysis including SNP assays and for RNA and definitive
FISH analyses, respectively. Eleven specimens were ex-
cluded after evaluation of the content of tumor area,
which was less than 30% of the whole specimen. Thus,
143 specimens from 141 patients were used for the
present study. All patients included in the analysis pro-
vided consent to participate in the study and to publish
the results. The study design was approved by the ethics
committee of Saitama Cancer Center.
Histological examination and immunohistochemistry
The core-needle specimens were evaluated microscop-
ically by pathologists, and classified according to the
system proposed by Elston and Ellis [16]. Positive rates
(%) for the ER and PgR were determined as a ratio of
positive cells to total cancer cells, and a value of 10%
or higher was defined as positive [17]. HER2 expres-
sion was defined as 0 to 3+ based on positive cell rates
and the intensity of IHC staining (HercepTest, DAKO,
Japan). Tumors showing moderate expression (2+) of
HER2 were also tested by FISH to clarify amplification
of the HER2 gene in paraffin specimens with the use
of PathVysion (Abbott, IL); positive FISH was defined
as a ratio of HER2 signals to centromere 17 signals of
>2.2. Thus, a HER2-positive reaction was defined as
either 3+ for IHC or 2+ for IHC with positive routine
FISH results.
P-cadherin (monoclonal mouse anti-human P-cadherin
clone 56, BD Transduction Lab.) was subjected toimmunohistochemical staining using an avidin-biotin
complex for the validation of genomic alterations identi-
fied by the SNP array in breast cancers.
Neoadjuvant and adjuvant chemotherapy and adjuvant
hormone therapy
Of 141 patients, 46 were determined as having a HER2+
tumor. Of these 46 patients, 37 received neoadjuvant
chemotherapy consisting of 12 weekly cycles of paclitaxel
with trastuzumab, and four cycles of cyclophosphamide,
epirubicin, and fluorouracil with concurrent trastuzumab
throughout the chemotherapy [1,18], and then underwent
surgery. Of the remaining 9 patients, 4 chose immediate
surgery, one received neoadjuvant chemotherapy without
trastuzumab, which was added after surgery, and three
with metastatic cancers at diagnosis and one with bilateral
tumors who chose treatment with trastuzumab, exe-
mestane, and radiation did not undergo surgery. All 5 pa-
tients who underwent surgery, received essentially the
same trastuzumab-containing chemotherapy, and were in-
cluded in the RFS analysis. Thus, pathological response
after neoadjuvant chemotherapy was evaluated in 37 tu-
mors, and RFS was evaluated for 42 patients. After
surgery, weekly trastuzumab therapy was given to HR- pa-
tients for 6 to 12 months [3], and the same therapy plus
hormone therapy; tamoxifen for premenopausal patients
and an aromatase inhibitor for postmenopausal patients,
was given to patients with a HR+ tumor.
Pathological response
Pathological response was assessed by a pathologist (M. K.)
according to the “histopathological criteria for assessment
of therapeutic response in breast cancer” proposed by the
Japanese Breast Cancer Society [19]. The extent of re-
sponses is classified as grade 0, 1, 2, and 3, which repre-
sents no response, slight response, marked response, and
complete response (CR), respectively. The grade 1 is fur-
ther classified as 1a and 1b, which represents mild re-
sponse indicating mild changes in cancer cells regardless of
the area, or marked changes in less than one third of
cancer cells, and moderate response indicating marked
changes in one third or more but less than two thirds of
tumor cells, respectively. Grade 2 indicates marked
changes in two thirds or more of tumor cells. Grade 3 indi-
cates necrosis or disappearance of all tumor cells.
Copy number and loss of heterozygosity (LOH) analysis
using SNP arrays
Affymetrix Mapping 250K-Nsp arrays (Affymetrix, Santa
Clara, CA) were used to analyze the chromosomal copy
number and LOH status in 143 tumors as described
previously [20]. Partial uniparental disomy (UPD) was
defined as a region of copy number-neutral LOH span-
ning over 3 Mb. Copy numbers and LOH were
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paired references as controls [21,22]. Amplification, gain,
and loss are defined as copy number ratios of >2.5, 1.2-
2.5, and <0.8, respectively.
Sixty-five genes were chosen for analyzing genomic al-
terations (gain, amplification, loss, and UPD) because of
previous studies reporting the involvement of these
genes in the neoplastic process of breast and other can-
cers. They were GPSM2, GSTM1, ATR, PIK3CA, MUC4,
INPP4B, TERT, MAP3K1, CCNB1, GCCR, FOXC1, DEK,
ID4, E2F3, NOTCH4, VEGFA, ESR1, HOXA9, CHIP,
MET, EGR3, FGFR1, MYC, CDKN2A, BAG1, CTSL2,
GATA3, PTEN, FGFR2, MKI67, SCUBE2, CCND1,
EMSY, HBXAP, GAB2, PGR, BIRC2, HER3, MDM2,
BRCA2, RB1, SPRY2, FOXA1, MTA1, RAD51, PTPN9,
IGFR1, CDH3, CDH1, CD68, TP53, AURKB, ERBB2/
HER2, GRB7, BECN1, BRCA1, MME1, TRIM25, BCAS3,
BIRC5, BCL2, MYBL2, AIB1, AURKA, and MMP11.
Quantitative PCR (QPCR) analysis of HER2 copy numbers
The QPCR analysis of HER2 copy numbers was carried
out with a Light Cycler (Roche Diagnostics, Indianapolis,
IN) and TaqMan probe (Roche Diagnostics). We
designed two regions of HER2 [HER2 5′ region, 5′-GAC
AGCCGCAGTAGCTTCTTA-3′ and 5′-CAAAATGGA
GCGCAGGTT-3′ (UPL#34); HER2 3′ region, 5′- GAG
AACCCCGAGTACTTGACAC-3′ and 5′- CCAGTAAT
AGAGGTTGTCGAAGG-3′ (UPL#63)] to quantify the
copy number of HER2. MOCS2 at 5q11.2 and SCN7A at
2q24.3, where the normal copy was identified by a SNP
array-based analysis, were used as reference genes.
Quantitative reverse-transcription PCR (QRT-PCR) analysis
of wild-type and variant HER2 transcripts
First strand cDNA was synthesized as described previ-
ously and the quantification of ACTB mRNA was
performed as a control to confirm the series of proce-
dures [20]. QRT-PCR using StepOne Plus and MGB
probes (Applied Biosystems, Foster City, CA) was used
to quantify the wild-type and variant HER2 mRNA,
Δ16HER2, containing an in-frame deletion. Primers used
were; wild-type HER2 5′-TCCTGTGTGGACCTGGA
TGA-3′ and 5′-GACCAGCAGAATGCCAACCA-3′,
probe 5′-AAGGGCTGCCCCGC-3′; Δ16 HER, 5′-CA
ACTGCACCCACTCCCC-3′, 5′-CTTGATGAGGATCC
CAAAGACC-3′, probe 5′-CATCATCTCTGCGGTGG
T-3′. The copy number for wild-type HER2 or Δ16HER2
was calculated in absolute units by comparing the signal
generated by the test samples to that generated by a set
of external plasmid standards containing the sequence of
wild-type HER2 or Δ16HER2 [23,24]. The stock plasmid
standard was created by ligating a PCR product containing
the wild-type HER2 or Δ16HER2 sequence into a plasmid
vector system, pGEM-T Easy Vector System I (Promega,Madison, WI), according to the manufacturer’s protocol.
The amount of plasmid DNA was determined by spectro-
photometric analyses of the insert-containing plasmid
DNA at A260 (1 optical density = 50 μg/ml plasmid DNA),
and the copy number per milliliter was determined based
on molecular weight. Dilutions of the plasmid ranged
from 10 to 300,000 copies per reaction, and quantitative
determination for clinical samples was carried out by
reading from this standard curve.
Analysis of TP53 and PIK3CA mutations
To detect specific point mutations, genomic DNA from
tumor samples was examined using PCR primers to
cover exons 2–10 of TP53, and to cover exons 9 and 20
of PIK3CA. PCR products were directly sequenced with
the BigDye Terminator v3.1 Cycle Sequencing Kit (Ap-
plied Biosystems).
Fluorescence in situ hybridization (FISH)
Some tumors showed discordance between HER2 genomic
status determined with SNP arrays or HER2 copy numbers
examined by QPCR and IHC (HercepTest, DAKO) with or
without FISH using paraffin specimens (PathVysion,
Abbott, Japan). Some of these tumors were subsequently
analyzed by FISH, using defrosted tumor specimens
stamped on slide glasses. The chromosome 17 alpha satel-
lite DNA was generated by PCR [25]. A BAC clone, RP11-
62N23, was used for detection of the HER2 region.
Statistical analysis
Patients were classified into two groups based on pres-
ence or absence of alterations of 65 cancer-associated
genes, and the two groups were further classified into
four groups based on HER2 genomic copy numbers,
hormone receptor status (HR+/−), or the response to
neoadjuvant chemotherapy (pCR vs. no pCR). Signifi-
cance of differences in clinical and genetic characteristics
between patient’s groups was examined using the chi-
square or Fisher’s exact test and Student’s t-test. RFS for
each group of patients classified on the basis of clinical
and genetic characteristics was estimated using the
Kaplan-Meier method, and compared using the log-rank
test. Time to failure was defined as the interval between
diagnosis and the time of first recurrence or last follow-
up. We also assessed the association between HER2 gen-
omic copy numbers and wild-type HER2 or Δ16HER2
mRNA levels by determining the Spearman rank correl-
ation coefficient and associated P-value.
Results
On the basis of routine methods, 77 tumors were classi-
fied as the HER2-/HR+ type, 28 as the HER2+/HR+ type,
18 as the HER2+/HR- type, and 20 as the HER2-/HR- type.
The 46 HER2+/HR+ and HER2+/HR- tumors are the
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aberrations, including gain, loss, amplification and UPD,
were examined in each tumor. Gain and amplification of
oncogenes were individually described in Additional file 1:
Table S1, however, they were combined and are referred to
as gain in the following analyses. All the 46 tumors showed
at least some chromosome aberrations.
Discordance ratios between the results of the routine and
definitive analyses on HER2 status
The routine method identified 46 tumors with the
HER2+/HR+/− type. Of the 46 tumors, 39 were classi-
fied as HER2 IHC 3+ and 7 as HER2 IHC 2+ with posi-
tive routine FISH results. SNP array patterns for the
HER2 locus disclosed gain in 38, normal in 6, and UPD
in two of the 46 tumors. Genomic HER2 copy numbers
were successfully examined in 45 of the 46 tumors by
QPCR; 37 tumors showed HER2 copy numbers with >2.0
indicating HER2 gain, and 8 showed genome copy num-
bers between 0.5 and 2.0, indicating no gain of HER2.
FISH analyses using defrosted tissue specimens were car-
ried out in 11 tumors for the validation of the results of
SNP array and QPCR analyses; SNP array patterns were
normal or showed UPD in 7, and gain in four. The data
obtained by the definitive FISH analysis were consistent
with those obtained by SNP array and QPCR analyses
(Additional file 1: Table S1). Accordingly, one tumor (No.
28), which was not examined by QPCR and identified to
have HER2 gain by SNP array, was included in the tu-
mors with HER2 copy numbers >2.0 for further analysis.
Thus, 4 HER2 IHC 3+ (8.7%) and 4 HER2 IHC 2+
(8.7%) tumors of the 46 tumors showed HER2 copy
numbers ≤ 2.0 by QPCR, and nonamplified HER2 by de-
finitive FISH analysis.
The relationship between HER2 genomic copy numbers
and clinical and genetic factors or levels of HER2 mRNA
Patients having tumors with lower HER2 copy numbers
(≤ 2.0) showed more difficulty in achieving pCR than
patients having tumors with higher HER2 copy numbers
(> 2.0) (P=0.019) (Table 1). Tumors with the lower
HER2 copy numbers had lower levels of wild-type HER2
mRNA (<400) than tumors with the higher HER2 copy
numbers (P=0.035), and showed higher incidences of
PIK3CA mutation (P=0.024), mutations and gain of
PIK3CA (P=0.005), loss of PTEN (P=0.008), or a com-
bined alteration of HER2 downstream genes, PIK3CA,
PTEN, and INPP4B (P=0.009) than tumors with the higher
HER2 copy numbers with respective genetic alterations.
HER2 transcripts were successfully examined in 41 tu-
mors, in all of which genomic copy numbers were also
examined by QPCR. The Spearman rank correlation co-
efficient analysis showed that HER2 genome copy num-
bers tended to be correlated with the levels of wild-typeHER2 mRNA (rS=0.280, P=0.076) and Δ16HER2 mRNA
(rS=0.297, P=0.059), but not with the percentages of
Δ16HER2 mRNA (rs=−0.200, P=0.202). The expression
levels of wild-type HER2 mRNA were correlated with
the expression levels of Δ16HER2 mRNA (rS=0.901,
P=1.05E-15).
Genetic aberrations and HER2 copy numbers and
transcripts detected in HER2+/HR+ and HER2+/HR-
tumors
Of 28 HR+ tumors, two were ER-negative/PgR-positive,
6 were ER-positive/PgR-negative, and 20 were ER-
positive/PgR-positive. There were no significant differ-
ences in the frequency of three aberrations (gain, loss,
and UPD) between 28 HER2+/HR+ tumors and 18
HER2+/HR- tumors. HR+/HER2+ tumors had lower
levels of wild-type HER2 mRNA (P=0.05) and Δ16HER2
mRNA (P<0.001) and a lower incidence of BIRC5 gain
(P=0.018) than HER2+/HR- tumors (Table 2). In
addition, HER2+/HR+ tumors tended to have higher in-
cidences of PTEN loss (P=0.058) and CDH3 gain
(P=0.058) than HER2+/HR- tumors. If we excluded the
8 patients with nonamplified HER2, the same genes
showed different incidences between the two types of
patients (Table 2, numbers in parentheses).
Response to neoadjuvant chemotherapy and RFS
between two groups of patients classified by clinical and
genetic characteristics in tumors
The response to neoadjuvant chemotherapy and RFS
were evaluated in 37 and 42, respectively, of 46 patients
(Table 3). Clinical factors, including age and clinical T
and N stages, did not affect the response to neoadjuvant
chemotherapy or RFS (data not shown). HR+ tumors
showed more difficulty in achieving pCR than HR- tu-
mors (P=0.009). Tumors with higher copy numbers of
HER2 and higher levels of Δ16HER2 mRNA entered
pCR more frequently than their counterparts (P=0.019
and P=0.020). Tumors with gain of FGFR1 or MYBL2
had more difficulty in achieving pCR than the tumors
without (P=0.035 and P=0.028). Tumors with loss of
PTEN had more difficulty entering pCR than the tumors
without (P=0.009). Tumors with a combination of muta-
tions and gain of PIK3CA, or combined aberrations of
the PI3K pathway genes, PIK3CA, PTEN and INPP4B
tended to have more difficulty entering pCR than tumors
without (P=0.08 and P=0.086).
The median follow-up time of the 42 patients was 41.2
months ranging from 19.3 to 85.3 months. There was no
difference in RFS between patients who achieved pCR
and those who did not (P=0.764) (Figure 1A) (Table 3).
Patients with lower HER2 genome copy numbers tended
to have worse RFS rates than those with higher HER2
genome copy numbers (P=0.095) (Figure 1B). In regard
Table 1 Differences in characteristics between two types
of breast cancer classified by HER2 copy numbers
HER2 copy
number ≤ 2.0
(n=8)
HER2 copy
number > 2
(n=38)
P-value
Hormone receptor status
(n=46)
Positive 6 22 0.368
Negative 2 16
Response to neoadjuvant
chemotherapy (n=37)
pCR (grade 3) 1 19 0.019
No pCR (grade 0–2) 6 11
Relapse after surgery
(n=42)
Not occurred 3 27 0.018
Occurred 5 7
Wild-type HER2 mRNA
(n=41)
< 400 5 18 0.035
≥ 400 0 18
Δ16HER2 mRNA (n=41)
< 4.5 4 15 0.107
≥ 4.5 1 21
Percentages of Δ16HER2
mRNA (n=41)
< 2.4% 3 32 0.087
≥ 2.4% 2 4
PI3KCA (exons 9 and 20)
(n=46)
Wild-type 5 35 0.024
Mutated 3 3
PI3KCA (exons 9 and 20)
(n=46)
Wild-type + Normal +
Loss + UPD
2 29 0.005
Mutated + Gain 6 9
PTEN (n=46)
Normal + Gain + UPD 5 36 0.008
Loss 3 2
INPP4B (n=46)
Normal + Gain + UPD 6 36 0.072
Loss 2 2
PI3KCA , PTEN, INPP4B
(n=46)
No aberrations* 1 24 0.009
Aberrations** 7 14
DEK (n=46)
Normal 3 27 0.07
Table 1 Differences in characteristics between two types
of breast cancer classified by HER2 copy numbers
(Continued)
Gain 5 11
FGFR1 (n=46)
Normal + Loss + UPD 4 27 0.248
Gain 4 11
CCND1 (n=46)
Normal + Loss 4 21 0.786
Gain 4 17
FOXA1 (n=46)
Normal + UPD 4 29 0.133
Gain 4 9
CDH3 (n=46)
Normal + Loss + UPD 6 35 0.158
Gain 2 3
BIRC5 (n=46)
Normal + Loss + UPD 6 23 0.441
Gain 2 15
MYBL2 (n=46)
Normal + Loss 4 28 0.186
Gain 4 10
AIB1 (n=46)
Normal + Loss 5 28 0.523
Gain 3 10
*No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain
or UPD of PTEN or INPP4B; **Aberrations, mutated and/or gain of PIK3CA, and
loss of PTEN or INPP4B.
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wild-type HER2 mRNA (< 400) in tumors showed worse
RFS rates than those with higher levels of the wild-type
mRNA (≥ 400) (P=0.022) (Figure 1C), and patients with
higher percentages of the Δ16HER2 transcript (≥ 2.4%)
in tumors showed worse RFS rates than those with lower
percentages (< 2.4%) (P=0.039) (Figure 1D). Patients
with a combination of mutations and gain of PIK3CA
(P=0.041), gain of DEK (P=0.006), CCND1 (P=0.043)),
FOXA1 (P=0.012) (Figure 1E), CDH3 (P=0.009) (Figure 1F),
BIRC5 (P=0.005) (Figure 2A), or AIB1 (P=0.017) (Figure 2B)
in tumors had worse RFS rates than patients without.
Next, we evaluated the pCR and RFS rates in 30 and
34 patients, respectively, excluding 7 and 8 patients with
HER2 copy numbers ≤ 2.0 from the 37 and 42 patients,
respectively, because data on patients only with a HER2-
amplified tumor may be important to show outcome of
the therapy given to a specified group of patients
(Additional file 2 Table S2). The positive HR status
(P=0.034), loss of PTEN (P=0.054), and gain of FGFR1
(P=0.077), MYBL2 (P=0.088) or AIB1 (P=0.088) indi-
cated or tended to indicate more difficulty in achieving
Table 2 Differences in characteristics between two types
of breast cancer classified by hormone receptor status
HER2+/HR+,
n=28 (n=22)
HER2+/HR-,
n=18 (n=16)
P-value
Response to neoadjuvant
chemotherapy
pCR (grade 3) 8 (8) 12 (11) 0.009 (0.034)
No pCR (grade 0–2) 14 (9) 3 (2)
HER2 copy numbers
≤ 2.0 6 2 0.368
> 2.0 22 16
Wild-type HER2 mRNA
< 400 16 (13) 7 (5) 0.05 (0.044)
≥ 400 7 (7) 11 (11)
Δ16HER2 mRNA
< 4.5 16 (13) 3 (2) <0.001 (0.001)
≥ 4.5 7 (7) 15 (14)
Percentages of Δ16HER2
mRNA
< 2.4% 20 (18) 15 (14) 0.745 (0.813)
≥ 2.4% 3 (2) 3 (2)
PI3KCA (exons 9 and 20)
Wild-type 24 (19) 16 (14) 0.755 (0.418)
Mutated 4 (1) 2 (2)
PI3KCA (exons 9 and 20)
Wild-type + Normal +
Loss + UPD
19 (18) 12 (12) 0.933 (0.611)
Mutated + Gain 9 (4) 6 (4)
PTEN
Normal + Gain + UPD 23 (20) 18 (16) 0.058 (0.215)
Loss 5 (2) 0 (0)
INPP4B
Normal + Gain + UPD 24 (20) 16 (14) 0.755 (0.735)
Loss 4 (2) 2 (2)
PI3KCA , PTEN, INPP4B
No aberrations* 15 (15) 10 (9) 0.895 (0.452)
Aberrations** 13 (7) 8 (7)
DEK
Normal 19 (17) 11 (11) 0.639 (0.556)
Gain 9 (5) 7 (5)
FGFR1
Normal + Loss + UPD 18 (15) 13 (12) 0.575 (0.871)
Gain 10 (7) 5 (4)
CCND1
Normal + Loss 16 (13) 9 (8) 0.635 (0.578)
Gain 12 (9) 9 (8)
FOXA1
Table 2 Differences in characteristics between two types
of breast cancer classified by hormone receptor status
(Continued)
Normal + UPD 20 (18) 13 (11) 0.953 (0.35)
Gain 8 (4) 5 (5)
CDH3
Normal + Loss + UPD 23 (19) 18 (16) 0.058 (0.124)
Gain 5 (3) 0 (0)
BIRC5
Normal + Loss + UPD 22 (17) 8 (6) 0.018 (0.013)
Gain 6 (5) 10 (10)
MYBL2
Normal + Loss 18 (15) 14 (13) 0.332 (0.366)
Gain 10 (7) 4 (3)
AIB1
Normal + Loss 19 (15) 14 (13) 0.466 (0.366)
Gain 9 (7) 4 (3)
Numbers in parentheses indicate patients’ numbers excluding 6 HER2+/HR+
and 2 HER2+/HR- patients whose tumors had HER2 copy numbers ≤ 2.0, and
P-values calculated from the numbers in the parentheses.
*No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain
or UPD of PTEN or INPP4B; **Aberrations, mutated and/or gain of PIK3CA, and
loss of PTEN or INPP4B.
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http://www.biomedcentral.com/1471-2407/13/241pCR than the respective counterparts. In contrast, pre-
dictive significance of Δ16HER2 < 4.5 for difficulty in
achieving pCR disappeared (P=0.132), and that of DEK
gain for more likely to achieve pCR newly appeared
(P=0.037). In regard to RFS, patients with wild-type
HER2 mRNA < 400 (P=0.066), mutation and gain of
PIK3CA (P=0.06), gain of CDH3 (P<0.001), BIRC5
(P=0.007), MYBL2 (P=0.013), or AIB1 (P=0.013) had or
tended to have worse RFS rates than those without. In
contrast, the prognostic significance of Δ16HER2 ≥ 2.4%
(P=0.1) and gain of DEK (P=0.108), CCND1 (P=0.247),
or FOXA1 (P=0.217) found in the 42 patients
disappeared in the 34 patients. Thus, the studies includ-
ing or excluding the 8 patients showed or suggested
prognostic significance of certain genetic alterations, es-
pecially those involved in the PI3K and ER pathways.Genetic characteristics that show significant differences in
RFS between HR+ tumors and HR- tumors
Patients having a HR+ tumor with mutations of PIK3CA
(P=0.006), a combination of mutations and gain of
PIK3CA (P=0.001), a combined aberration of PIK3CA,
PTEN and INPP4B (P=0.002), and gain of FOXA1
(P=0.002), CDH3 (P=0.007), BIRC5 (P=0.016), MYBL2
(P=0.015), and AIB1 (P=0.006) had worse RFS rates than
patients having a HR+ tumor without (Table 4). How-
ever, no such significance of the genetic aberrations was
found in patients with a HR- tumor. It is noteworthy
Table 3 RFS and pCR rates for 42 patients classified by clinical and genetic characteristics
Response to neoadjuvant
chemotherapy
Relapse-free survival
pCR No pCR P-value No. of Patients (No. of events) 3-year estimates 95% CI P-value
All patients 20 17 42 (12) 0.72 0.55-0.89
Response to neoadjuvant chemotherapy
pCR (grade 3) 20 (4) 0.73 0.52-0.93 0.764
No pCR (grade 0~2) 17 (5) 0.86 0.67-1.04
Hormone receptors
Positive 8 14 0.009 25 (7) 0.76 0.58-0.95 0.914
Negative 12 3 17 (5) 0.69 0.42-0.95
HER2 copy numbers
≤ 2.0 1 6 0.019 8 (5) 0.57 0.20-0.94 0.095
> 2.0 19 11 34 (7) 0.78 0.62-0.94
Wild-type HER2 mRNA
< 400 8 9 0.208 20 (8) 0.61 0.40-0.83 0.022
≥ 400 11 5 17 (2) 0.92 0.76-1.07
Δ16HER2 mRNA
< 4.5 5 8 0.020 17 (5) 0.72 0.50-0.93 0.314
≥ 4.5 15 4 20 (5) 0.75 0.53-0.96
Percentages of Δ16HER2 mRNA
< 2.4% 17 11 0.581 31 (6) 0.79 0.63-0.94 0.039
≥ 2.4% 5 1 6 (4) 0.50 0.10-0.90
PIK3CA
Wild-type 18 14 0.498 36 (9) 0.79 0.64-0.94 0.171
Mutated 2 3 6 (3) 0.42 −0.02-0.85
PIK3CA
Wild-type + Normal + Loss + UPD 16 9 0.08 28 (6) 0.85 0.70-1.01 0.041
Mutated + Gain 4 8 14 (6) 0.56 0.29-0.83
PTEN
Normal + Gain + UPD 20 12 0.009 37 (11) 0.73 0.56-0.89 0.705
Loss 0 5 5 (1) 0.80 0.45-1.15
INPP4B
Normal + Gain + UPD 17 16 0.373 36 (8) 0.79 0.64-0.94 0.095
Loss 3 1 6 (4) 0.50 0.10-0.90
PI3KCA , PTEN, INPP4B
No aberrations* 14 6 0.086 22 (4) 0.81 0.60-1.01 0.195
Aberrations** 6 11 20 (8) 0.67 0.45-0.89
DEK
Normal 13 14 0.236 28 (5) 0.88 0.75-1.01 0.006
Gain 7 3 14 (7) 0.44 0.14-0.75
FGFR1
Normal + Loss + UPD 17 9 0.035 29 (9) 0.75 0.48-0.86 0.641
Gain 3 8 13 (3) 0.92 0.76-1.07
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Table 3 RFS and pCR rates for 42 patients classified by clinical and genetic characteristics (Continued)
CCND1
Normal + Loss 11 12 0.33 25 (4) 0.84 0.68-1.01 0.043
Gain 9 5 17 (8) 0.58 0.33-0.84
FOXA1
Normal + UPD 15 13 0.917 30 (6) 0.80 0.64-0.96 0.012
Gain 5 4 12 (6) 0.60 0.29-0.91
CDH3
Normal + Loss + UPD 19 14 0.217 37 (8) 0.79 0.64-0.94 0.009
Gain 1 3 5 (4) 0.40 −0.03-0.83
BIRC5
Normal + Loss + UPD 14 13 0.659 27 (5) 0.82 0.66-0.98 0.005
Gain 6 4 15 (7) 0.56 0.25-0.88
MYBL2
Normal + Loss 18 10 0.028 30 (7) 0.80 0.64-0.96 0.053
Gain 2 7 12 (5) 0.58 0.24-0.91
AIB1
Normal + Loss 18 11 0.063 31 (7) 0.81 0.65-0.96 0.017
Gain 2 6 11 (5) 0.52 0.15-0.89
CI, confidence interval; *No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain or UPD of PTEN or INPP4B; **Aberrations, mutated and/or
gain of PIK3CA, and loss of PTEN or INPP4B.
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rate between 20 patients having a HR+ or HR- tumor
with aberrations of the PI3K pathway genes and 22
patients having a HR+ or HR- tumor with no such aber-
rations (Table 3 and Figure 2C, P=0.195), 13 patients
having a HR+ tumor with the same aberrations had a
worse RFS rate than 12 patients having a HR+ tumor
with no such aberrations (Table 4, Figure 2D, P=0.002).
When we excluded the 8 patients with HER2 copy num-
bers ≤ 2.0 in tumors, the prognostic significance of the
genetic alterations was also demonstrated in 19 patients
with a HR+ tumor (Additional file 3: Table S3, Figure 2F,
P=0.03), but not in the 34 patients with a HR+ or HR-
tumor (Additional file 2: Table S2, Figure 2E, P=0.248).
Clinical and genetic characteristics that predict pCR or
RFS, or both
Patients with higher HER2 copy numbers, a combination
of mutations and gain of PIK3CA, and gain of MYBL2
and AIB1 had or tended to have worse pCR and RFS
rates than the respective counterparts (Table 3). In con-
trast, patients with positive HR status, lower levels of
Δ16HER2 transcript, loss of PTEN, and gain of FGFR1
had more difficulty in achieving pCR, but not worse RFS
rates than the respective counterparts, whereas patients
with lower levels of wild-type HER2 mRNA, higher per-
centages of Δ16HER2 mRNA, and gain of DEK, CCND1,
FOXA1, CDH3, or BIRC5 had worse RFS rates, but not
more difficulty in achieving pCR than the respectivecounterparts. Gain of MYC, EMSY, and AURKA, TP53
mutations, and other genetic aberrations did not affect
pCR or RFS (data not shown). Thus, some genetic
aberrations indicated either the response to the chemo-
therapy or the RFS, and others indicated both. These
findings also indicated that genetic aberrations that cor-
relate with difficulty in achieving pCR and those that
correlate with worse RFS rates do not always overlap.
Correlation of immunohistochemical findings of CDH3 with
hormone receptor status, genetic alterations, and RFS
All 5 tumors with gain of CDH3 belonged to the HR+
type, and patients having a tumor with gain of CDH3
had worse RFS rates than patients without. To validate
the findings shown by the SNP array, we performed im-
munohistochemical staining of P-cadherin encoded by
CDH3. While 5 tumors with CDH3 gain showed 1+, 2+,
or 3+ P-cadherin expression, 8 of 33 tumors with CDH3
loss or a normal CDH3 genetic status showed negative
P-cadherin expression. While all 18 HR- tumors showed
1+, 2+, or 3+ P-cadherin expression, 8 of 22 HR+ tu-
mors showed negative P-cadherin expression (P<0.01).
Patients with P-cadherin 3+ expression/HR+ tumors had
worse RFS rates than patients with P-cadherin negative
or 1+ expression/HR+ tumors (P=0.032). Thus, while all
HR- tumors showed P-cadherin expression, some HR+ tu-
mors were negative for P-cadherin expression, indicating
that the staining patterns and their prognostic implica-
tions differed between the two types of tumors.
Figure 1 Relapse-free survival curves for patients classified by clinical and genetic characteristics. (A) Patients who achieved pCR and
those who did not, (B) patients with HER2 copy numbers ≤ 2.0 and those with HER2 copy numbers >2.0 in the tumors, (C) patients with wild-
type HER2 mRNA < 400 and those with wild-type HER2 mRNA ≥ 400 in the tumors, (D) patients with Δ16HER2 mRNA < 2.4% and those with
Δ16HER2 mRNA ≥ 2.4% in the tumors, (E) patients with gain of FOXA1 and those with a normal copy or UPD of FOXA1 in the tumors, (F) patients
with gain of CDH3 and those with a normal copy, loss, or UPD of CDH3 in the tumors.
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In the present SNP array-based study of 46 HER2+
breast cancers, we evaluated clinical and genetic factors
that indicate pCR and RFS in patients who were treated
with trastuzumab-containing neoadjuvant chemother-
apy. SNP array analysis has a merit to detect whole gen-
omic aberrations at once, and therefore could find a
predictive or prognostic impact of combined genomic
aberrations. Such an attempt seems not to have been
made before. The 46 tumors were selected based on a
routine HER2 study using IHC with or without FISH in
deparaffinized tissue samples. We found discordance be-
tween results of the routine analysis and the present
SNP and QPCR analysis with FISH in defrosted tissue
samples in 17.4% (8/46) of tumors; 4 IHC 3+ (8.7%) and
4 IHC 2+ (8.7%) tumors. Previous studies reported the
IHC3+, FISH negative type in 0.9%-18.5% of tumors ex-
amined [9], and the percentage of 8.7% shown in the
present study may be comparable to or a little higherthan the previous results. Another discordance of 4 pa-
tients with the IHC 2+ and nonamplified HER2 type
may be caused by the difficulty of FISH analysis using
needle biopsied tissues embedded in paraffin. It is diffi-
cult to compare this percentage of 8.7% with those of
other series, because there have been no comparable
studies reported.
Overexpression of protein occurs not only by mRNA
overexpression, but also by post-transcriptional, transla-
tional and protein degradation regulation [26]. HER2 is
efficiently ubiquitinated and downregulated by the
chaperone binding ubiquitin ligase CHIP/STUB1 [27].
Recently, Jan et al. studied the expression and correlations
among TID1, CHIP, and HER2 in a total of 183 breast
cancer histology sections using IHC and immunoblotting
assay, and found that the immunohistochemical expres-
sion of TID1 and CHIP were positively correlated with
each other but were both inversely correlated to that of
HER2 [28]. These findings suggest that down-regulation
Figure 2 Relapse-free survival curves for patients classified by genetic characteristics. (A) Patients with gain of BIRC5 and those with a
normal copy, loss, or UPD of BIRC5 in the tumors, (B) patients with gain of AIB1 and those with a normal copy or loss of AIB1 in the tumors, (C)
20 patients with HR+ or HR- tumors with combined aberrations of PIK3CA, PTEN, and INPP4B, and 22 patients with HR+ or HR- tumors with no
aberrations of PIK3CA, PTEN, and INPP4B, (D) 13 patients with HR+ tumors with combined aberrations of PIK3CA, PTEN, and INPP4B, and 12 patients
with HR+ tumors with no aberrations of PIK3CA, PTEN, and INPP4B, (E) 13 patients with HR+ or HR- tumors with combined aberrations of PIK3CA,
PTEN, and INPP4B, and 21 patients with HR+ or HR- tumors with no aberrations of PIK3CA, PTEN, and INPP4B, and (F) 7 patients with HR+ tumors
with combined aberrations of PIK3CA, PTEN, and INPP4B, and 12 patients with HR+ tumors with no aberrations of PIK3CA, PTEN, and INPP4B.
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venting its degradation. In a study of metastatic breast
cancer with the HER2 IHC2+/3+ and nonamplified HER2
type, patients treated with trastuzumab plus chemother-
apy had better progression-free survival than those treated
with chemotherapy alone (P=0.03), suggesting the pres-
ence of the true single-gene overexpressers in the study
population [11]. Thus, some HER2-single-gene over-
expressers were not the results of technical shortcomings
of HER2 IHC, but could be the results of disruption of
HER2 protein degradation occurring in the tumor cells.
Overexpression of MYCN caused by the disruption of the
protein degradation but not by the amplification indicated
poor outcome in patients with neuroblastoma [29].
The present study indicated that the patients with
nonamplified HER2 showed more difficulty in achievingpCR and more frequent relapse than those with HER2
amplification. Unexpectedly, we found that tumors with
the lower HER2 copy numbers had more frequent alter-
ations in the PI3K pathway genes than those with the
higher copy numbers (Table 1). Alterations of the PI3K
pathway genes were reported to be associated with poor
response to HER2-targeted therapy in patients with
HER2+ tumors [30], and this finding concurs with the
present finding indicating the poor outcome of patients
having a tumor with HER2 IHC 2+/3+ and nonamplified
HER2. These findings support the statement that FISH
analysis should be the primary HER2 testing for patients
who are candidates for HER2-targeted therapies [9].
In regard to the relationship between clinical and gen-
etic factors and RFS, patients with various genetic
changes in tumors identified by SNP array had or tended
Table 4 RFS in patients with a HR-positive or HR–negative tumor classified by clinical and genetic characteristics
Hormone receptor-positive tumors (n=25) Hormone receptor-negative tumors (n=17)
No. of Patients
(No. of events)
3-year
estimates 95% CI P-value
No. of Patients
(No. of events)
3-year
estimates 95% CI P-value
All patients 25 (7) 0.76 0.58-0.95 17 (5) 0.69 0.42-0.95
Response to neoadjuvant CT
pCR (grade 3) 8 (1) 0.81 0.58-1.05 0.485 12 (3) 1.0 - 0.906
No pCR (grade 0~2) 14(4) 0.77 0.49-1.05 3 (1) 0.69 0.39-0.99
HER2 copy numbers
≤ 2.0 6 (4) 0.60 0.17-1.03 0.12 2 (1) 0.50 −0.19-1.19 NA
> 2.0 19 (3) 0.81 0.62-1.01 15 (4) 0.74 0.47-1.00
Wild-type HER2 mRNA
< 400 14 (5) 0.67 0.43-0.91 0.054 6 (3) 0.33 −0.17-0.83 0.196
≥ 400 6 (0) 1.0 - 11 (2) 0.86 0.60-1.12
Δ16HER2 mRNA
< 4.5 14 (4) 0.74 0.53-0.96 0.283 3 (1) 0 0 0.832
≥ 4.5 6 (1) 0.80 0.45-1.15 14 (4) 0.72 0.45-1.00
Percentages of Δ16HER2 mRNA
< 2.4% 17 (3) 0.78 0.59-0.97 0.143 14 (3) 0.77 0.49-1.00 0.073
≥ 2.4% 3 (2) 0.67 0.13-1.20 3 (2) 0.33 −0.20-0.87
PIK3CA (exons 9 and 20)
Wild-type 21 (4) 0.89 0.75-1.03 0.006 15 (5) 0.65 0.37-0.94 NA
Mutated 4 (3) 0.25 −0.17-0.67 2 (0) 1.0 -
PIK3CA (exons 9 and 20)
Wild-type + Norma l+ Loss +UPD 16 (1) 1.0 - 0.001 12 (5) 0.57 0.25-0.89 0.2
Mutated + Gain 9 (6) 0.40 0.06-0.74 5 (0) 1.0 -
PTEN
Normal + Gain + UPD 20 (6) 0.76 0.55-0.97 0.814 17 (5) 0.69 0.42-0.95 NA
Loss 5 (1) 0.80 0.45-1.15 0 - -
INPP4B
Normal + Gain + UPD 21 (4) 0.83 0.65-1.01 0.133 15 (4) 0.75 0.49-1.00 NA
Loss 4 (3) 0.50 0.01-0.99 2 (1) 0.50 −0.19-1.19
PI3KCA, PTEN, INPP4B
No aberrations* 12 (0) 1.0 - 0.002 10 (4) 0.59 0.23-0.95 0.312
Aberrations** 13 (7) 0.60 0.32-0.87 7 (1) 0.75 0.33-1.17
DEK
Normal 17 (3) 0.86 0.68-1.04 0.067 11 (2) 0.91 0.74-1.08 0.106
Gain 8 (4) 0.51 0.11-0.91 6 (3) 0.30 −0.17-0.77
FGFR1
Normal + Loss + UPD 17 (5) 0.72 0.49-0.96 0.94 12 (4) 0.59 0.28-0.91 0.69
Gain 8 (2) 0.86 0.60-1.12 5 (1) 1.0 -
CCND1
Normal + Loss 16 (2) 0.91 0.74-1.08 0.075 9 (2) 0.71 0.36-1.06 0.433
Gain 9 (5) 0.51 0.16-0.85 8 (3) 0.67 0.29-1.04
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Table 4 RFS in patients with a HR-positive or HR–negative tumor classified by clinical and genetic characteristics
(Continued)
FOXA1
Normal + UPD 17 (1) 0.92 0.76-1.07 0.002 13 (5) 0.66 0.39-0.93 0.504
Gain 8 (6) 0.45 0.08-0.82 4 (0) 1.0 -
CDH3
Normal + Loss + UPD 20 (3) 0.88 0.73-1.04 0.007 17 (5) 0.69 0.42-0.95 NA
Gain 5 (4) 0.40 −0.03-0.83 0 - -
BIRC5
Normal + Loss + UPD 19 (3) 0.86 0.68-1.04 0.016 8 (2) 0.75 0.45-1.05 0.235
Gain 6 (4) 0.44 0.01-0.88 9 (3) 0.59 0.10-1.09
MYBL2
Normal + Loss 16 (2) 0.92 0.78-1.07 0.015 14 (5) 0.66 0.39-0.94 0.539
Gain 9 (5) 0.48 0.11-0.84 3 (0) 1.0 -
AIB1
Normal + Loss 17 (2) 0.93 0.79-1.06 0.006 14 (5) 0.66 0.39-0.94 0.539
Gain 8 (5) 0.39 −0.01-0.78 3 (0) 1.0 -
CI, confidence interval; CT, chemotherapy; NA, not applicable; *No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain, or UPD of PTEN or
INPP4B; **Aberrations, mutated and/or gain of PIK3CA, and loss of PTEN or INPP4B.
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Previous studies reported that overexpression of these
genes identified by various methods was associated with
a poor outcome in patients with breast cancer [31-37].
Thus, the present study indicated that the results of the
SNP array analysis detecting gain of specific genes and
those of other analyses detecting overexpression of the
gene products were mostly consistent.
When the prognostic implications of the genetic aber-
rations were separately examined in HR+ and HR- tu-
mors, a combination of mutations and gain of PIK3CA,
a combined aberration of the PI3K pathway genes, and
gain of FOXA1, CDH3, BIRC5, MYBL2, and AIB1 indi-
cated worse RFS rates only in patients with a HR+
tumor (Table 4). It is noteworthy that the incidences of
the most genetic changes did not differ between the two
types of tumors (Table 2). We confirmed the result of a
study reporting that increased PI3K pathway activity was
associated with poor outcome for patients treated with
HER2-targeting therapy [30], and newly found that the
prognostic significance of the alterations in the PI3K and
ER pathway genes applied only to the patients with a HR
+ tumor (Table 4). FOXA1, a forkhead family transcrip-
tion factor, is essential for optimum expression of ER
and estrogen responsive genes. Although one study
reported that FOXA1 expression was correlated with the
luminal A subtype and a favorable outcome [38], others
depicted a complicated picture of FOXA1 as a partici-
pant in multiple signaling pathways in breast cancer,
which are both oncogenic and tumor suppressive [33].
Actually, a recent study reported co-expression of ER
and FOXA1 in metastatic breast cancer samples,indicating oncogenic activities of FOXA1 [39]. AIB1 is a
nuclear receptor coactivator that interacts with ERs in a
ligand-dependent fashion and enhances estrogen-
dependent transcription. Harigopal et al. reported AIB1
activation to be mediated by crosstalk with other signal-
ing kinases such as growth factor receptors including
MAPK, which can be activated by HER2 in a ligand-
independent fashion [40]. AIB1 is considered as a key
factor in the regulation of tumor growth and carcino-
genesis. In addition, patients with AIB1-positive tumors
identified by IHC showed worse RFS rates than those
with AIB1-negative tumors [40]. These findings indicate
that crosstalk between the PI3K and ER pathways is
causally involved in resistance to the chemotherapy with
trastuzumab, and thus, that hormone receptor status im-
pacted the prognostic significance of genomic alterations
in HER2+ tumors.
The present study also showed that gain of DEK and
BIRC5 genes, which seems not to be involved in the
PI3K or ER pathway, had clear prognostic significance in
patients with breast cancer (Table 3), suggesting pres-
ence of other pathways exhibiting crosstalk with the
PI3K or ER pathway. Lu et al. reported that HER2-
mediated up-regulation of survivin expression contrib-
uted to Taxol resistance through a survivin-mediated
faster exit from mitosis [41]. Xia et al. showed that ac-
quired resistance to lapatinib in the BT474 cell line was
associated with a switch in the regulation of survivin
from HER2 to ER [42]. Thus, various roles of survivin in
chemotherapy resistance may contribute to the prognos-
tic significance of BIRC5 gain in the present series of pa-
tients with HR+ and HR- breast cancers.
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exon 16 (Δ16HER2) has been detected in human breast
cancers [12]. Mitra and colleagues showed that ectopic
expression of Δ16HER2, but not wild-type HER2 mRNA,
promoted receptor dimerization, cell invasion, and
trastuzumab resistance in the NIH3T3 and MCF7 cell
lines [13]. Recently, a mouse line that transgenically ex-
presses the Δ16HER2 transcript has been generated and
all the transgenic females developed multifocal mam-
mary tumors with a rapid onset [14]. This oncogenic iso-
form has been associated with trastuzumab resistance in
various in vitro and transgenic mouse studies [12,14].
The present study showed that levels of the wild-type
HER2 transcript and those of the Δ16HER2 transcript
were correlated, and that there was no difference in the
RFS rate between patients with higher levels of Δ16HER2
mRNA and those without. In addition, we also found that
patients with higher percentages of the Δ16HER2 mRNA
(≥ 2.4%) and lower levels of the wild-type HER2 mRNA (<
400) were likely to have recurrence. The decreased RFS
rates for patients with lower levels of wild-type HER2
mRNA may be explained by the decreased susceptibility
to trastuzumab in patients with such tumors. The patients
with the higher percentage of Δ16HER2 mRNA also had
the lower level of wild-type HER2 mRNA, and this
lower level might have resulted in a lower denominator
and hence the higher percentages of Δ16HER2 mRNA.
Thus, the poor prognosis of patients with the higher
percentage of Δ16HER2 mRNA may be related to the
lower levels of the wild-type HER2 mRNA, or to pres-
ently unknown mechanisms.
The present study showed no difference in RFS be-
tween patients who attained pCR and those who did not.
Previous studies indicated better overall survivals for pa-
tients with pCR than those with no pCR [2,3]. von
Minckwits and colleagues studied pCR and its prognos-
tic impact on survival in intrinsic breast cancer subtypes
and concluded that pCR is a suitable surrogate end point
for patients with HER2+ (nonluminal) but not luminal
B/HER2+ breast cancer [43]. More recently, results of a
meta-analysis showed that patients with a HR-/HER2+
or HR+/HER2+ tumor who achieved pCR had greater
event-free survival than those with the respective subtype
of tumor who did not [44]. The contradictory finding of
the present study might be caused by the small sample
size and inclusion of HR+/HER2+ and HR-/HER2+ breast
cancer samples.
Several clinical trials have been carried out to improve
the outcome of patients with HER2+ tumors. Two trials
reported that the combination of an aromatase inhibitor
with trastuzumab or lapatinib improved outcome for pa-
tients with HER2+/HR+ metastatic breast cancer com-
pared with an aromatase inhibitor alone [45,46]. Both
trials showed better progression-free survival for thepatients treated with the combination. These studies
were undertaken because the crosstalk between the PI3K
and ER pathways could cause resistance to trastuzumab
and anti-hormone agents. In addition, one phase 2 and
another phase 3 clinical trials were carried out using a
combination of lapatinib and trastuzumab with or
without cytotoxic chemotherapy for patients with a
HER2+/HR+ or HER2+/HR- early stage tumor, and both
studies showed improved pCR rates [47,48]. These stud-
ies were undertaken because primary and acquired re-
sistance to both agents could be overcome, their partly
non-overlapping mechanisms of action, and the well-
characterized synergistic interaction between them could
be expected in patients with HER2+ breast cancer. The
present study showed that the PI3K and ER pathway
genes were specifically altered in HER2+/HR+ tumors of
patients who subsequently relapsed after receiving neo-
adjuvant chemotherapy with trastuzumab. Lapatinib tar-
gets the intracellular ATP domain of HER2, preventing
self-phosphorylation and subsequent activation of the
PI3K and MAPK signal pathways [5]. It may be reasonable
to add lapatinib to the present trastuzumab-containing
chemotherapy for patients with a HER2+/HR+ tumor to
overcome the resistance due to the altered PI3K pathway
genes and to obtain a better outcome.
Conclusion
The present study showed that 17.4% of tumors with
positive HER2 testing had nonamplified HER2, and pa-
tients with this type of tumor showed difficulty in
achieving pCR and frequent relapses, supporting FISH
analysis as a primary HER2 testing. The study also
disclosed that alterations of the PI3K and ER pathway
genes indicated worse RFS rates in patients with a HR+
but not with a HR- tumor who were treated with neo-
adjuvant chemotherapy with trastuzumab. It may be
reasonable to add lapatinib to the present trastuzumab-
containing chemotherapy for patients with a HER2+/HR+
tumor to overcome the resistance due to the altered PI3K
pathway genes and to obtain a better outcome.
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